摘要
糖尿病肾病作为糖尿病的一种慢性并发症,近年来其发病率随着糖尿病的发病率不断上升也呈现逐年上升的趋势。肾素‐血管紧张素‐醛固酮系统(RAAS)的激活在糖尿病肾病的发生发展中有着极其重要的地位,使用RAAS抑制剂可以明显地控制血压、减少尿蛋白、减轻肾小球高滤过、延缓肾间质纤维化。一些大型的临床试验已经证实抑制RAAS的治疗可以明显减轻糖尿病肾病患者微量白蛋白尿及大量白蛋白尿的产生及发展,延缓糖尿病肾病的进展,减少终末期肾病的发病率。但目前关于联合应用RAAS阻滞剂因其不良事件的明显增加还需要我们进一步探索解决。
Diabetic nephropathy as a chronic complications of diabetes, its incidence in recent years along with the increasing incidence of diabetes also showed a trend of rising year. Renin-angiotensin aldosterone system activation in the occurrence of diabetic nephropathy development has the extremely important status, use of RAAS inhibitors can significantly control high blood pressure, reduce urine protein, reduce glomerular filtration, and delay the renal interstitial fibrosis. Some large clinical trials have confirmed that inhibiting renin-angiotensin aldosterone system treatment can significantly reduce microalbuminuria and macroalbuminuria in patients with diabetic nephropathy, delay the progress of diabetic nephropathy, and reduce the incidence of end-stage renal disease. But the combined use of RAAS blocker due to its significantly increased adverse events also needs our further research.
出处
《中华临床医师杂志（电子版）》
CAS
2015年第4期1-5,共5页
Chinese Journal of Clinicians(Electronic Edition)
